NanoViricides Inc (NNVC)

[BonelessCat]

All three are important. All three indicate a high efficacy not seen in nearly all other drugs.

They didn't just live longer, the result of the most effeictive test had 100% of the mice survive to the end of the 100% fatal protocol.

There wasn't just a reduction of lesions. The most effective viricide showed an average of 2 lesions as opposed to more than 20 for all other non-viricide mice. Lesions relate directly to mortality even more so in real worl where they are associated with secondary infections and deadly congestion.

The amount of residual viral matter will be a major indicator of the ability of other virus strains and species recombining with that residual matter. It also relates to the need for prolonged viricide treatment for immune compromised patients. If there is effectively no material left, then treatment can stop, but if there is any statistically measurable cell load, then treatment would need to continue for some time after the symptoms disappeared. Finally, it would also indicate that nearly all, if not all, of the viral particle replicants were swept up by the the viricide before they could duplicate. Certainly would answer some of the questions last week regarding the likelihood of FluCide encountering influenza particles in the blood.

If the cellular viral material is greatly reduced, then I expect some validation that FluCide is the lead candidate.